Tamara Brisibe, PharmD<sup>1</sup>; Long Nguyen, PharmD<sup>1</sup>; Ben Penley, PharmD, MS<sup>1</sup>; Helen Haileselassie, PharmD, BCPS<sup>1</sup>; Kimberly Westrich, MA<sup>2</sup> <sup>1</sup>Cencora, Conshohocken, PA, USA, <sup>2</sup>National Pharmaceutical Council, Washington, DC, USA

### Background

- The Institute for Clinical and Economic Review (ICER) publishes approximately 8 to 10 evidence reports per year that evaluate the cost-effectiveness and comparative clinical value of new drugs. Their value assessment framework (VAF) allows for standardized analysis of the comparative cost and clinical value of these therapies.<sup>1-3</sup>
- In March 2023, ICER released their white paper "Advancing Health Technology Assessment" Methods that Support Health Equity," to give recommendations for health technology assessment (HTA) bodies to help societies improve health equity for racial, ethnic, and socially disadvantaged groups.<sup>4</sup>
- In September 2023, ICER finalized their VAF with specific modifications to their methodology and procedures that address health equity concerns, most of which were adapted from their health equity white paper released in March 2023.<sup>4</sup>
- Understanding how ICER continues to incorporate health equity into their new framework is important for both biopharma companies and healthcare decision-makers, as considerations of health equity are increasingly becoming an integral part of healthcare decision-making.

### **Objective**

• To examine ICER's integration of health equity factors within their VAF through a review of their Final Evidence Reports since the release of their white paper on health equity.

### Methods

- All of ICER's publicly available Draft Evidence Reports (N=3) and Final Evidence Reports (N=3) published between March 2023 and October 2023 were reviewed.
- We identified 7 parameters ICER outlined in their white paper to consider health equity within their Final Evidence Reports (**Figure 1**), which were further divided into 8 measurable equity factors.
- Health equity factors were extracted and compared between the Final Evidence Reports and their respective Draft Evidence Report to determine the final implementation of health quality measures.
- A quantitative comparison of the 8 measurable health equity-related factors was performed by 2 independent reviewers.
- Two independent reviewers conducted a qualitative assessment of the final policy recommendations to summarize the responsibilities and actions required from various stakeholders to improve health equity.

### Figure 1. Health equity parameters and measurable equity factors in ICER's white paper

1	Selecting healthcare interventions for assessment		Discussion of di background
2	Engaging patients and patient groups in the HTA process	>	Evidence of eng patient population
3	Evaluating diversity of participants in clinical trials	>	Participant-to-di (PDPR) score, I Rating Tool scor
4	Analyzing results by subpopulations	>	Subpopulation a
5	Measuring the opportunity to reduce health disparities	>	Health Improver Score, distribution analysis (DCEA
6	Promoting health equity through quantitative methods of cost analysis		DCEA, multiple (MCDA)
7	Promoting health equity through deliberative methods of appraisal		California Techr (CTAF) voting o equity

Key: CTAF - California Technology Assessment Forum; DCEA - distributional cost-effectiveness analysis; HIDI - Health Improvement Distributional Index; HTA – health technology assessment; ICER – Institute for Clinical and Economic Review; MCDA – multiple disease criteria decision analysis; PDPR – participant-to-disease-prevalence ratio.

# CGUCOLO

# A preliminary assessment of ICER's new HTA methods that support health equity

disparities in report

ngagement with the diverse tions in report background

disease prevalence ratio ICER Sample Diversity

analysis

ement Distribution Index (HIDI) tional cost-effectiveness

e criteria decision analysis

nnology Assessment Forum on the impact on health

### Methods (cont.)

- The ICER Clinical Trial Diversity Rating Tool is a framework developed by ICER to consistently and objectively evaluate clinical trial diversity. An overall diversity rating is provided for the following demographic characteristics: race/ethnicity, sex, and age.<sup>4</sup>
- The participant-to-disease prevalence ratio (PDPR) score is an ICER-developed metric that assigns a score between 0 and 3 to each demographic category based on the estimated PDPRs. Using the cumulative score and pre-defined cut points, a rating of "good," "fair," or "poor" is used to communicate the overall level of racial and ethnic diversity in a clinical trial.<sup>4</sup>

### Results

### Analysis of reports

• Overall, the application of the 8 health equity factors was not consistent between the Draft and Final Evidence Reports (Figure 2).

### Figure 2. Equity-related factors across ICER Draft and Final Evidence Reports

Discussion of disparities in report background Evidence of engagement with a diverse patient population in report background

PDPR score

ICER Clinical Trial Diversity Rating Tool score

Subpopulation analysis

HIDI score

DCEA/MCDA


CTAF voting on health equity measures

Final Evidence Reports (N=3)

Key: CTAF – California Technology Assessment Forum; DCEA – distributional cost-effectiveness analysis; HIDI – Health Improvement Distribution Index; ICER – Institute for Clinical and Economic Review; MCDA – multiple criteria decision analysis; PDPR – participant-to-disease prevalence ratio.

- For all Final Evidence Reports (N=3) released between March 2023 and October 2023, ICER most consistently incorporated the following health equity-related factors:
- Discussion of disparities in the report background
- Evidence of engagement with a diverse patient population in the report background
- Inclusion of health equity considerations in criteria for California Technology Assessment Forum (CTAF) voting
- 2 of the 3 Final Evidence Reports did not include subpopulation analyses, PDPR scores, and ICER clinical trial diversity rating scores.<sup>a</sup>
- Quantitative methods for considering health equity (eg, DCEA, MCDA, or other equity-related cost-effectiveness analyses) were not used in any of the Final **Evidence Reports.**
- Overall, there were not many differences in the included health equity factors when Draft and Final Evidence Reports were compared. Health Improvement Distribution Index (HIDI) score, PDPR score, and ICER Clinical Trial Diversity Rating scores were infrequently included in Draft Evidence Reports but included in Final Evidence Reports. Due to ICER's evaluation process, CTAF voting was only included in Final Evidence Reports.<sup>5</sup>
- All Final Evidence Reports included voting on society's goal of reducing health inequities within CTAF votes. The most common equity-related factors referenced in CTAF votes were race/ethnicity, disease-related disparities, and socioeconomic factors (Table 1).

<sup>a</sup>ICER noted in the respective reports that the small sample size prevented the evaluation of the heterogeneity of treatment effect based on age, genotype, or other factors. Additionally, ICER noted an inability to calculate the HIDI in one evidence report due to uncertainties in the prevalence estimates for the disease state.



### **Results (cont.)**

**Other Benefits or Disadvantages**"

Equity factors	n (%)
Race/Ethnicity	3 (100%)
Socioeconomic	2 (66%)
Geographic	1 (33%)
Disease-related	3 (100%)
Gender	0

Key: CTAF – California Technology Assessment Forum.

• In all Final Evidence Reports (N=3) reviewed between March 2023 and October 2023, ICER most frequently provided recommendations for how different stakeholders might engage in opportunities to address health equity (Table 2).

### Table 2. ICER key health equity policy recommendations per stakeholder

Stakeholders	ICER
All stakeholders	All sta cures race, g health
Manufacturers	Work metho
Payers	Consi deterr benef
Clinicians and clinical specialty societies	Devel
Patient organizations	<ul> <li>Deve</li> <li>Collar</li> <li>recru</li> </ul>

elop programs to deliver culturally sensitive information laborate with manufacturers and researchers to target the uitment and retention of diverse populations for clinical trials Key: ICER – Institute for Clinical and Economic Review.

### Limitations

- in value assessment.

### Conclusions

- **Evidence Reports.**

**References: 1.** Penley B, et al. An assessment of the evolving methods and role of health equity factors in ICER's Final Evidence Reports. Poster presented at: ISPOR 2023; May 7-10, 2023; Boston, MA. 2. Westrich K, Buelt L. The more things change, the more they stay the same? Reviewing ICER's revised value assessment framework. November 1, 2023. Accessed March 15, 2024. https://www.amerisourcebergen.com/insights 3. Muir JM, et al. Front Pharmacol. 2023;14:1197259. 4. Institute for Clinical and Economic Review. Advancing health technology assessment methods that support health equity. March 15, 2023. Accessed March 15, 2024. https://icer.org/wp-content/uploads/2022/07/ICER Advancing-Health-Technology-Assessment-Methods-that-Support-Health-Equity\_040523.pdf 5. Institute for Clinical and Economic Review. ICER processes for conducting value assessments. September 25, 2023. Accessed March 15, 2024. https://icer.org/wpcontent/uploads/2023/09

> **Presented at ISPOR 2024** May 5-8, 2024 | Atlanta, GA Funded by Cencora

## Table 1. Equity-related factors frequently identified in CTAF votes for "Potential"

### recommendations

akeholders should take steps to facilitate access to potential in a way that does not exacerbate health inequities (eg, by geography, and health literacy) that characterize the US hcare system

with communities and patient groups to develop reliable ods for recruitment and retention of diverse populations

ider wraparound programs that help address barriers to social minants of health (eg, transportation, case management, fit counseling)

lop programs to recruit and retain a diverse workforce

• This analysis only included health equity methods and factors highlighted within ICER's white paper and did not encompass all methods for considering health equity

• The results from this analysis are only preliminary, as only a small sample size of Final Evidence Reports was published during the analysis period.

• Although these results are limited in scope due to the small number of assessments published since the introduction of the new methodology, the findings suggest that ICER has made progress in incorporating their new HTA methods in their Final

### • There remains an opportunity to more consistently incorporate both qualitative and quantitative measures of health equity in the consideration of product value.